维普期刊资源整合服务平台（V6.5）

156篇 您的检索式：作者名="Campone"

选中清除导出查看参考文献查看引证文献引用追踪共8页首页上一页第1页下一页末页 /8 跳转

	题名	作者	年代	出处	被引量
1	Safety and pharmacokinetics of paclitaxel and the oral roTOR inhibitor everolimus in advanced solid tumours显示文摘	Campone M Levy V Bourbouloux E	2009	Br J Cancer2009，100，2：	1
2	Everolimus in postmenopausal hormone-receptor-positive advanced breast Cancer显示文摘	Baselga J Campone M Piccart M		0，，06：	1
3	A randomized,phase Ⅱ,three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer显示文摘	Rugo HS Campone M Amadori D	2013	Breast Cancer Res Treat2013，139，2：	1
4	Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase Ⅰ study显示文摘	Bonneterre J Campone M Koralewski P	2007	Cancer Chemotherapy and Pharmacology2007，60，3：	1
5	PhaseⅡstudy of vinorelbine(alternating intravenous and oral)in combination with docetaxel as first-lime chemotherapy in metastatic breast cancer显示文摘	campone M Blasinska Morawiec M Tekiela A	2009	Gastric Cancer2009，10，2：	1
6	Everolimus inpostmenopausal hormone- receptor- positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1
7	Everolimus in postmenopausal hormone receptor positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	New England Journal of Medicine2012，366，6：	1
8	Everolim- us plus exemestane for hormone-receptor-positive, hu- man epidermal growth factor receptor-2-negative ad- vanced breast cancer: overall survival results from BO- LERO-2显示文摘	Piccart M Hortobagyi GN Campone M	2014	Ann Oncol2014，25，12：	1
9	Everolimus in postmeno- pausal hormone- receptor- positive advanced breast cancer 显示文摘	Baselga J Campone M Piceart M	2012	N Engl J Med2012，366，6：	1
10	Induction of chemoresistance in HL260 cells concomitantly causes a resistance to apoptosis and the synthesis of p-glycoprtein 显示文摘	Campone M Vavesseur F Lecabellec MT	2001	Leakemia2001，15，：	1
11	Everolimus plus exemestane for hormone-receptor-positive,human epidermal growth factor receptor-2-negative advanced breast cancer:overall survival results from BOLERO-2?显示文摘	Piccart M Hortobagyi GN Campone M	2014	Ann Oncol2014，25，12：	1
12	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1
13	Targeting EGFR with dovinib (TKI258) : preclinical and clinical data in breast cancer 显示文摘	Andre F Bachelot T Campone M	2013	Clin Cancer Res2013，19，13：	1
14	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer 显示文摘	BASELGA J CAMPONE M PICCART M	2012	New Eng J Med2012，366，6：	1
15	Treatment Planning and Image Guidance for Radiofrequency Ablations of Large Tumors 显示文摘	Ren H Campon N E Yaniv Z	2014	IEEE Journal of Biomedical & Health Informatics2014，18，3：	1
16	Multicentre phase Ⅱ and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme显示文摘	RAYMOND E CAMPONE M STUPP R et ol	2002	Eur J Cancer2002，38，10：	1
17	Everolimus in postmeno- pausal hormone-receptor-positive advanced breast cancer 显示文摘	Baselga J Campone M Piccart M	2012	N Engl J Med2012，366，6：	1
18	Extended benefit from sequential administration of docetaxel after standard fluoroura- cil,epirubicin, and cyclophosphamide regimen for node-positive breast cancer:the 8-year follow-up results of the UNICANCER- PACS01 trial显示文摘	Coudent B Asselain B Campone M	2012	Oncoloqist2012，17，7：	1
19	Targeting ErbB receptors in breast cancer 显示文摘	FUMOLEAU P CAMPONE M COUDERT B	2007	Bull Cancer2007，94，7：	1
20	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer显示文摘	Baselga J Campone M Piccart M		0，，06：	1

返回顶部每页显示：

共8页首页上一页第1页下一页末页 /8 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示